1. Home
  2. IVDA vs OGEN Comparison

IVDA vs OGEN Comparison

Compare IVDA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

HOLD

Current Price

$0.31

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.60

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVDA
OGEN
Founded
2003
1996
Country
United States
United States
Employees
32
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
2.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
IVDA
OGEN
Price
$0.31
$0.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
252.0K
40.9K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.11
52 Week High
$2.70
$9.16

Technical Indicators

Market Signals
Indicator
IVDA
OGEN
Relative Strength Index (RSI) 51.52 47.51
Support Level $0.27 $0.56
Resistance Level $0.34 $0.66
Average True Range (ATR) 0.03 0.04
MACD -0.00 0.00
Stochastic Oscillator 42.07 44.49

Price Performance

Historical Comparison
IVDA
OGEN

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: